Melanoma Clinical Trials in Philadelphia

Showing 201-220 of 326 trials

Circulating Tumor Material in Colorectal Cancer and Melanoma

NCT02907086

Observational study to allow the collection of blood and medical information to evaluate the role of circulating tumor material in patients with colorectal cancer and melanoma

Colorectal Cancer and Melanoma

Abramson Cancer Center at Penn Medicine7 participantsStarted Jul 2017

Philadelphia, Pennsylvania, United States

COMPLETEDNA< 1 mile

Multicenter Selective Lymphadenectomy Trial II (MSLT-II)

NCT00297895

Subjects must be diagnosed with melanoma. All subjects receive sentinel lymphadenectomy. If the subject is sentinel node positive and meets study requirements, the subject is randomized to receive either (1) completion lymphadenectomy (2) observation with nodal ultrasound. Subjects are then followed for 10 years.

Melanoma

Saint John's Cancer Institute1,939 participantsStarted Sep 2004

San Diego, California, United States • Santa Monica, California, United States • Colorado Springs, Colorado, United States +60 more locations

Circulating Tumor Material in Colorectal Cancer and Melanoma

Multicenter Selective Lymphadenectomy Trial II (MSLT-II)

Melanoma Trials in Other Cities

A Study Comparing Vemurafenib Versus Vemurafenib Plus Cobimetinib in Participants With Metastatic Melanoma

Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers

Safety Study of MGA271 in Refractory Cancer

Efficacy Study of Pharmacokinetic(PK)/Pharmacodynamic(PD) Relationship of Monotherapy MORAb-004 in Metastatic Melanoma

Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064)

Early FDG PET in Melanoma

A CD8 Positron Emission Tomography With Computed Tomography (PET/CT) Study Using ⁸⁹Zr Df-IAB22M2C in Patients With Metastatic Melanoma Receiving Bempegaldesleukin (NKTR-214) and Nivolumab

A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma

A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)

PV-10 vs Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma

A Study of PLX2853 in Advanced Malignancies.

Safety Study of Enoblituzumab (MGA271) in Combination With Ipilimumab in Refractory Cancer

A Phase 1 Study of Nivolumab (BMS-936558) in Subjects With Advanced or Recurrent Malignancies

A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV Melanoma

A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies

Phase I/II Study of PDR001 in Patients With Advanced Malignancies

Trial of PI-88 With Dacarbazine in Patients With Metastatic Melanoma

Single-arm Trial to Evaluate the Role of the Immune Response to Talimogene Laherparepvec in Unresected Melanoma

Other Conditions in Philadelphia